^
    Back
    Association details:
    Biomarker:AKT2 expression
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:CCT128930 (AKT inhibitor, p70S6K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    ASH 2018
    Title:

    Akt2 Mediates Glucocorticoid Resistance in Acute Lymphoblastic Leukemia through FoxO3a/Bim Axis and Serves As a Direct Target for Resistance Reversal

    Published date:
    11/01/2018
    Excerpt:
    By western blot analysis we observed the expression of Akt2 in intrinsically resistant T-ALL cells....Selective inhibition of Akt2 with CCT128930 more significantly enhances the FoxO3a/Bim signaling pathway, increases DEX-mediated killing of resistant T-ALL cells (F) and effectively reverses GC resistance than Akt1 inhibitor in vitro and in vivo.
    DOI:
    https://doi.org/10.1182/blood-2018-99-110496